KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Enriqueta Felip et al. · Annals of Oncology · 2019
Cited by 80 works. doi:10.1093/annonc/mdz453.002